✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Semaglutide

Released: Last reviewed:

GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Semaglutide overview

GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).

Semaglutide at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Pivotal trials

Related pages